SCHEMBL5155318

SCHEMBL5155318

COc1ccc2cc(OCCCCOc3ccc4c5ccccc5n(CCC(=O)O)c4c3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 10/20 0.56
PSEN2 P49810 10/20 0.56
APH1B Q8WW43 10/20 0.56
NCSTN Q92542 10/20 0.56
APH1A Q96BI3 10/20 0.56
PSENEN Q9NZ42 10/20 0.56
FABP4 P15090 3/20 0.54
FABP5 Q01469 3/20 0.54
FABP3 P05413 1/20 0.54
DYRK1A Q13627 2/20 0.54
PTGS2 P35354 1/20 0.49
MCL1 Q07820 2/20 0.47
KMO O15229 1/20 0.47
PLA2G2A P14555 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152373 0.94 PSEN1 (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5154856 0.93 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5156736 0.92 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5151312 0.92 FABP4 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5152744 0.89 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5151535 0.89 FABP4 (0.62) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5152270 0.89 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5149617 0.89 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5152361 0.88 PSEN1 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5152282 0.88 PSEN1 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US claimed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
WO-2007071456-A1 FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor PTGER2, PTGER1, PTGDR2 PSEN1 2971/4885PSEN2 1240/4885APH1B 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.